

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHANGE OF AUDITOR**

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”) pursuant to the Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

### **RESIGNATION OF AUDITOR**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that Crowe (HK) CPA Limited (“**Crowe**”) has resigned as the auditor of the Company and its subsidiaries with effect from 14 December 2022 after taking into account many factors including the professional risk associated with the audit, the level of audit fees and its available internal resources in the light of current work flows. Crowe and the Company could not reach a consensus on the audit service fee regarding the annual audit for the financial year ending 31 December 2022.

Crowe has included in its resignation letter to the Company that there are no matters in connection with its resignation as the auditor of the Company and its subsidiaries that need to be brought to the attention of the shareholders (the “**Shareholders**”) of the Company. The Board and the audit committee of the Board (the “**Audit Committee**”) have confirmed that there are no other matters or circumstances in respect of the change of auditor that need to be brought to the attention of the Shareholders.

The Board further confirmed that Crowe has not yet commenced any review or audit work on the financial statements of the Group for the financial year ending 31 December 2022. The Board believes that the change of auditor will not have any significant impact on the annual audit and the release of annual results of the Group for the year ending 31 December 2022.

The Board and the Audit Committee are of the view that the change of auditor would enable the Company to carry out effective cost control and reduce the overall operating expenses of the Company to better cope with the future business development of the Group. This also complies with good corporate governance practice as it enhances the independence of the auditor of the Company, and is in the interest of the Company and its Shareholders as a whole.

The Board would like to take this opportunity to express its sincere gratitude to Crowe for its professional services rendered to the Company in the past years.

#### **APPOINTMENT OF AUDITOR**

The Board, with the recommendation from the Audit Committee has resolved to appoint Moore Stephens CPA Limited (“**Moore Stephens**”) as the new auditor of the Company with effect from 14 December 2022 to fill the casual vacancy following the resignation of Crowe. Moore Stephens shall hold office until the conclusion of the next annual general meeting of the Company.

The Board welcomes the appointment of Moore Stephens as the new auditor of the Company.

By order of the Board  
**China NT Pharma Group Company Limited**  
**Ng Tit**  
*Chairman*

Hong Kong, 14 December 2022

*As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Chin Yu; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Pan Fei and Dr. Zhao Yubiao.*